Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have a diagnosis of primary-progressive, secondary-progressive, progressive-relapsing, or relapsing-remitting MS per revised McDonald Committee criteria \[McDonald 2001; Polman 2005\] as defined by Lublin and Reingold \[Lublin and Reingold 1996\] of at least 3 months duration~* Must have an Expanded Disability Status Scale (EDSS) score of 4 to 7, inclusive~* Must have walking impairment, as deemed by the Investigator~Key Exclusion Criteria:~* History of human immunodeficiency virus (HIV)~* Presence of acute or chronic hepatitis. Subjects who have evidence of prior hepatitis infection that has been serologically confirmed as resolved are not excluded from study participation~* Known allergy to fampridine, pyridine-containing substances, or any of the inactive ingredients in the prolonged-release fampridine tablet~* Creatinine clearance (CrCl) of \<80 mL/min~* History of malignant disease~* Presence of pulmonary disease~* A body mass index (BMI) ≥40 (BMI formula: BMI = mass \[kg\]/\[height(m)\]2)~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fampridine 10 mg BID (Type: EXPERIMENTAL): Prolonged-release fampridine 10 mg twice daily (BID) for up to 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matched placebo 10 mg BID for up to 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).